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Abstract
Background: Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a
hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in gliomas that are functionally
defined by their capacity for extensive self-renewal and formation of secondary tumors that phenocopy the original tumors.
As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to
cancer stem cell biology as these cells share characteristics with normal stem cells.
Methodology/Principal Findings: Based on previous methods that we and others have employed, tumor cell populations
were enriched or depleted for cancer stem cells using the stem cell marker CD133 (Prominin-1). We characterized c-Myc
expression in matched tumor cell populations using real time PCR, immunoblotting, immunofluorescence and flow
cytometry. Here we report that c-Myc is highly expressed in glioma cancer stem cells relative to non-stem glioma cells. To
interrogate the significance of c-Myc expression in glioma cancer stem cells, we targeted its expression using lentivirally
transduced short hairpin RNA (shRNA). Knockdown of c-Myc in glioma cancer stem cells reduced proliferation with
concomitant cell cycle arrest in the G0/G1 phase and increased apoptosis. Non-stem glioma cells displayed limited
dependence on c-Myc expression for survival and proliferation. Further, glioma cancer stem cells with decreased c-Myc
levels failed to form neurospheres in vitro or tumors when xenotransplanted into the brains of immunocompromised mice.
Conclusions/Significance: These findings support a central role of c-Myc in regulating proliferation and survival of glioma
cancer stem cells. Targeting core stem cell pathways may offer improved therapeutic approaches for advanced cancers.
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Introduction
The emerging cancer stem cell model suggests that tumors are
organized in a hierarchy with a subpopulation of cancer stem cells
responsible for tumor maintenance and progression. Cancer stem
cells are highly tumorigenic and phenocopy the original tumors in
rodent xenograft models. Depletion of the cancer stem cell
population greatly impairs the potential to initiate xenograft tumor
formation of the bulk tumors [1,2]. The cancer stem cell population
also contributes to solid tumor angiogenesis [3], metastasis [4], and
resistance to chemotherapy and radiotherapy [3,5,6,7,8,9]. While
this model has been validated in a growing list of haematopoietic
and solid tumors, the molecular signaling pathways orchestrating
the biology of cancer stem cells remain to be elucidated.
The c-Myc oncoprotein has been extensively studied for its
instrumental role in proliferation and growth of normal and
neoplastic cells. Deregulated c-Myc is found in diverse human
tumors and is often associated with advanced malignancy and poor
prognosis [10]. As c-Myc has been recently recognized as an
important regulator of stem cell biology, it may serve as a link
connecting malignancy and ‘‘stemness’’ [11]. In either normal or
transformed cells, c-Myc alone activates an embryonic stem cell-like
transcriptional module, which strongly correlates with tumor
metastasis and mortality [12]. Ectopic c-Myc expression in
transformed human keratinocytes dramatically increases the cancer
stem cell fraction and enhances tumorigenicity [12]. Introduction of
c-Myc with othertranscription factors (includingOct3/4,Sox2,and
Klf4) generates induced pluripotent stem (iPS) cells from differen-
tiated cells [13]. Excluding c-Myc from this combination without
eliminating endogenous c-Myc expression, drastically reduces the
efficiency of iPS cell production [13,14,15,16]. While all of these
data suggest a role for c-Myc in maintaining stem cells, other
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described. Conditional knockout of c-Myc in mouse bone marrow
does not prevent proliferation or self-renewal of haematopoietic
stem cells [17]. It rather results in accumulation of haematopoietic
stem cells in bone marrow, suggesting that c-Myc specifically
controls the interaction between haematopoietic stem cells and their
niches. Additionally, over-expression of c-Myc-estrogen receptor
fusion protein in human epidermal stem cells drives differentiation
rather than proliferation [18,19].
Because of the recognized functions of c-Myc in both normal
stem cell biology and neural malignancy, we investigated the role
of c-Myc in human glioma cancer stem cells. Gliomas are the most
common primary intrinsic tumor type of the central nervous
system. High grade gliomas (World Health Organization grades
III and IV) are among the most lethal human malignancies [20].
In glioma, c-Myc expression correlates with the grade of
malignancy [21]. Expression of c-Myc driven by the glial fibrillary
acidic protein (GFAP)-promoter in developing mouse astroglia
induces tumors that resemble human glioblastoma multiforme
[22]. In this mouse model, the tumor mass contains fast dividing
subpopulation that express c-Myc and relatively quiescent tumor
cells that lack c-Myc expression [22]. We have now determined
that the glioma cancer stem cells expressed higher levels of c-Myc
relative to matched non-stem tumor cells and the activity of c-Myc
is required for proliferation, growth, and survival of glioma cancer
stem cells. Loss of c-Myc abolished xenograft formation by glioma
cancer stem cells, underscoring a key role of c-Myc in glioma
cancer stem cell maintenance.
Results
Glioma cancer stem cells express high levels of c-Myc
To investigate the biological functions of c-Myc in regulation of
glioma cancer stem cells, we first determined expression of c-Myc in
these cells. Short term cultures enriched or depleted for cancer stem
cells were derived from human brain tumor specimens using
CD133 selection and characterized as we have previously
demonstrated [9]. Quantitative real-time PCR revealed that
CD133+ glioma cells expressed higher c-Myc mRNA levels than
matched CD1332 glioma cells (Figure 1A). The differential mRNA
levels translated into higher levels of c-Myc protein in CD133+
glioma cells than matched CD1332 cells (Figure 1B). Consistent
with prior reports [23,24], the cancer stem cell-enriched fractions
also expressed high levels of Olig2, a marker of adult neural
multipotent progenitors (Figure 1B). To directly measure the
expression of c-Myc in human brain tumors, we further evaluated
c-Myc expression by flow cytometry in both CD133+ and CD1332
fractions of glioma cells acutely isolated from human surgical biopsy
specimens without in vitro culture (Figure 1C). Approximately half of
the CD133+ cells were high in c-Myc expression, whereas nearly
90% CD1332 cells expressed low levels of c-Myc (Figure 1D). We
further examined c-Myc expression in glioma cancer stem cells
using sections generated from acutely frozen human glioma surgical
specimens. Because co-staining with CD133 was not compatible
with antigen retrieval method required for c-Myc staining, we co-
stained c-Myc with another neural stem cell marker Nestin. Greater
than 90% of Nestin positive glioma cells were also c-Myc positive
(Figure 1E). These data suggest that c-Myc is highly expressed in
glioma cancer stem cells.
c-Myc regulates cell cycle progression and proliferation
of glioma cancer stem cells
c-Myc plays a key role in regulating cellular proliferation by
controlling the expression of cell cycle proteins. To interrogate the
role of c-Myc in the cell cycle of glioma cancer stem cells, we
targeted c-Myc expression by infection with lentivirus expressing
shRNA specific to c-Myc. Two different shRNAs efficiently
decreased c-Myc expression in both CD1332 and CD133+
glioma cells as shown by quantitative real-time PCR and
immunoblotting (Figure 2A and 2B). Similar results were found
in another tumor specimen (T4597, data not shown). Depletion of
c-Myc significantly reduced the S phase cell population with
concomitant increase of the G0/G1 cell population in CD133+
cells (p,0.001, Figure 3). In contrast, CD1332 cells displayed a
lower rate of proliferation with a smaller S phase population than
matched CD133+ cells (Figure 3 and data not shown), and the cell
cycle progression in CD1332 cells was not significantly altered by
knockdown of c-Myc. Regulation of the cell cycle by c-Myc is
commonly mediated through transcriptional regulation of the
cyclins and the cyclin-dependent kinase inhibitors, including
cyclins D1,D 2, and E and p21
WAF1/CIP1 [26,27] (http://www.
myc-cancer-gene.org). Attenuating c-Myc expression specifically
reduced cyclin D1 protein levels, but not cyclins D2 or E, in
CD133+ cells (Figure 2B). Additionally, p21
WAF1/CIP1 protein
levels were upregulated in cancer stem cells depleted of c-Myc,
whereas p53 levels were only moderately altered (Figure 2B).
Quantitative real-time PCR showed a similar pattern of cyclin D1
and p21
WAF1/CIP1 regulation at mRNA levels by c-Myc in CD133+
cells, suggesting c-Myc regulated these two genes at the level of
transcription. In striking contrast, cyclin D1 and p21
WAF1/CIP1 were
minimally altered by knocking down c-Myc at either the mRNA or
protein levels in CD1332 cells. Notably, basal cyclin D1 levels were
higher in CD133+ cells than matched CD1332 cells, whereas
cyclin D2 and cyclin E levels were higher in CD1332 cells,
suggesting that cyclin D1, but not cyclins D2 or E, is critical for the
G1/S transition in CD133+ glioma cells. Taken together, these
results suggest that c-Myc regulates cell cycle progression in glioma
cancer stem cells, at least partially, through controlling expression of
cyclin D1 and p21
WAF1/CIP1.
Previous reports demonstrated that brain tumor stem cells
isolated from human surgical biopsy specimens were actively
proliferative in vitro [28,29], but the numbers of matched CD1332
tumor cells barely increased after a week of culture. Our data that
the relatively high expression of c-Myc in glioma cancer stem cells
is essential for their cell cycle regulation suggest that the growth of
these cells may also require c-Myc activity. As demonstrated by
growth curve assays, the total number of control CD133+ cells
increased roughly six or seven fold over five days, whereas
CD133+ cells depleted of c-Myc did not increase or decreased in
number (Figure 4). Conversely, growth of the CD1332 population
was only moderately attenuated with c-Myc knockdown (Figure 4).
These results suggest that c-Myc preferentially contributes to
sustained growth of tumor initiating cells.
Loss of c-Myc induces apoptosis in glioma cancer stem
cells
c-Myc regulates not only cellular proliferation but also cellular
survival. In concordance with a role in survival, we noted an
accumulation of dead cells in the CD133+ fraction depleted of c-Myc
expression during the growth curve experiments that was not present
in controls (data not shown). Conversely, indications of cell death
were limited in matched CD1332 cells, regardless of c-Myc status,
suggesting that loss of c-Myc might specifically induce apoptosis in
CD133+ cells. The role of c-Myc in regulating apoptosis remains
controversial. Previous reports have demonstrated that c-Myc
promotes apoptosis in cancer cell lines and various normal cell types,
whereas downregulation of c-Myc also leads to apoptosis under
certain circumstances [30,31,32,33]. To distinguish the anti-apoptot-
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quantified apoptotic cell populations following knockdown of c-Myc.
Annexin V staining revealed that depletion of c-Myc induced
apoptosis in CD133+ glioma cells, whereas the control CD133+ cells
containedaminimalapoptoticpopulation(Figure5A,C).Incontrast,
the CD1332 population had only background staining of Annexin V
regardless of c-Myc levels. Consistent with these data, the combined
caspase 3/7 activity was elevated in CD133+ cells following c-Myc
knockdown, but not in matched CD1332cells (Figure5B,D).Taken
together, these data suggest that c-Myc is a survival factor for glioma
cancer stem cells.
Loss of c-Myc impairs neurosphere formation by glioma
cancer stem cells
Sharing certain key characteristics of normal stem cells, cancer
stem cells are capable of self-renewal, which allows sustained
maintenance of this subpopulation and expansion of the whole
tumor. Serial neurosphere formation assay has been utilized as a
surrogate of the self-renewal capacity of neural stem cells [34], and
was recently employed in the brain tumor stem cells [9,28]. In
primary neurosphere formation assays, approximately 15% of
control CD133+ cells formed neurospheres, whereas very few
spheres were formed by cells depleted of c-Myc (Figure 6A).
Neurospheresdevelopedin100%ofwellsinthecontrolgroup when
plated at a density of 100 cells/well and in 80–85% wells when
plated at 10 cells/well (Figure 6B). In contrast, neurospheres were
formed by cells depleted of c-Myc expression in only 10% (shRNA-
1) or 30% (shRNA-2) of wells when plated at a density of 100 cells/
well, while no spheres were found when these cells were plated at 10
cells/well. Of note, neurospheres formed by cells with reduced c-
Myc expression were markedly smaller than the spheres formed by
the control cells (Figure 6C) and merely met the minimal criteria to
be scored in our experiments. Lack of neurospheres formed by
glioma cancer stem cells depleted of c-Myc suggests impaired self-
renewal. However, assessing secondary neurosphere formation was
precluded because very few spheres were generated in the
knockdown groups in the primary assay and the neurospheres
had limited viability. These studies therefore could not definitely
determine if c-Myc expression is required for self-renewal of glioma
cancerstem cells.However,itis expected that self-renewalofglioma
cancer stem cells is inhibited by knockdown of c-Myc, based on our
observations that glioma cancer stem cells failed to proliferate and
underwent apoptosis upon knockdown of c-Myc.
Knockdown of c-Myc inhibits the tumorigenic potential
of glioma cancer stem cells
Based on the requirement of c-Myc activity for cell cycle
progression, growth and survival, of CD133+ glioma cells in
Figure 2. c-Myc modulates cell cycle regulators of glioma cancer stem cells. (A) Early passage (,P5) T3359 glioblastoma CD1332 or
CD133+ cells were infected by lentivirus directing expression of either non-targeting shRNA (NT) or c-Myc specific shRNAs (sh-1 and sh-2). The mRNA
levels of c-Myc, p21
WAF1/CIP1, cyclin D1 (cycD1) and cyclin D2 (cycD2) were determined by quantitative real-time PCR 3 days after infection. (B) Protein
levels of c-Myc, p53, cyclin D1, cyclin D2, cyclin E and p21
WAF1/CIP1 were determined by immunoblotting.
doi:10.1371/journal.pone.0003769.g002
Figure 1. c-Myc is highly expressed in glioma cancer stem cells. (A) CD1332 and CD133+ cells were isolated from glioma surgical biopsy
specimens passaged short-term in immunocompromised mice and briefly cultured. Total RNA was isolated from both CD1332 and CD133+ cells.
cDNA was prepared by reverse transcription. Expression of c-Myc was then determined by quantitative real-time PCR and normalized to b-actin and
HPRT1. Relative mRNA levels of c-Myc in CD1332 cells were assigned a value of 1. Data are represented as mean6S.E.M in this and all subsequent
graphs (#:p ,0.001). (B) Total cellular lysates were resolved by SDS-PAGE. Protein levels of c-Myc and Olig2 were determined by immunoblotting.
Actin was blotted as the loading control. (C) Glioma cells were isolated directly from human surgical biopsy specimens, fixed in 4% paraformaldehyde
following dissociation, labeled with anti-CD133-APC and anti-c-Myc-FITC, and subjected to FACS analysis. (D) Percentage of cells expressing high
levels of c-Myc within either the CD1332 fraction or the CD133+ fraction was demonstrated (#:p ,0.001). (E) Sections of freshly frozen human
glioma surgical biopsy specimens were fixed and co-stained for c-Myc (green) and Nestin (red). Nuclei were counterstained with Hoechst 33342.
Representative images (6306) were demonstrated.
doi:10.1371/journal.pone.0003769.g001
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tumorigenic potential. CD133+ glioma cells were infected with
non-targeting control lentivirus or lentivirus expressing c-Myc
shRNA. Following puromycin selection, 5000 cells of each group
were injected into the brains of nude mouse in quadruplicate.
100% of mice bearing control cells rapidly developed neurologic
signs and displayed large tumors on histopathology composed of
pleomorphic cells featuring high nuclear to cytoplasmic ratios,
prominent nucleoli with minimal cytoplasm, brisk mitotic activity
and central geographic necrosis, consistent with a high grade glial
malignancy (Figure 7). In contrast, no mice injected with cells
depleted of c-Myc expression developed signs and after 100 days
demonstrated no evidence of neoplastic cells (Figure 7). Thus, c-
Myc appears to be essential for cancer stem cells to form tumors.
Discussion
The cancer stem cell hypothesis has engendered significant
controversy, but the presence of heterogeneity of tumor cells in
some cancers is well recognized. Tumor cells that display stem cell-
like characteristics and initiate xenograft tumors have been
purified from an increasing number of cancers, including leukemia
[35,36], brain [28,29], breast [37], colorectal [38,39], pancreatic
[40], and head and neck cancers [41]. These cancer stem cells are
functionally defined through assays of self-renewal and serial
xenotransplantation assays in rodent models. Experiments dem-
onstrate that the tumorigenic potential of cancer stem cells is at
least several magnitudes higher than the bulk tumors. For
example, glioma cancer stem cells enriched by selection of the
CD133 surface antigen form orthotopic xenograft tumors with 500
cells in athymic nude mice, whereas 2610
6 CD1332 cells cannot
[9]. In line with the potent tumorigenicity of brain tumor stem
cells, we demonstrated here that CD133+ glioma cancer stem cells
highly expressed the c-Myc oncoprotein. FACS analysis demon-
strated that at least half of CD133+ cells acutely dissociated from
human surgical biopsy specimens had high levels of c-Myc,
whereas the majority (.85%) of CD1332 cells were c-Myc-low
(Figure 1D). Similar co-expression of c-Myc and a stem cell
marker, Nestin, was identified directly on human surgical biopsy
specimen sections (Figure 1E). Notably, glioma cancer stem cells
Figure 3. c-Myc induces cell cycle arrest of glioma cancer stem cells. (A, B) Early passage (,P5) T3359 glioblastoma CD1332 or CD133+ cells
were infected by lentivirus directing expression of either non-targeting shRNA (NT) or c-Myc specific shRNAs (sh-1 and sh-2). Three days after
infection, cells were fixed in 75% ethanol and labeled with 10 mg/ml propidium iodide. Cell cycle distribution was determined by flow cytometry. (A)
Data were generated from three independent experiments. *, p,0.05; #,p ,0.001 with one-way ANOVA comparison of the control groups to the
corresponding c-Myc knockdown groups. (B) Representitive FACS plots are displayed. M1-sub G0 phase; M2-G0/G1 phase; M3-S phase; M4-G2/M
phase.
doi:10.1371/journal.pone.0003769.g003
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protein (Figure 2B, lanes 5 and 6) that were higher than the c-Myc
levels found in CD1332 cells expressing non-targeting shRNA
(Figure 2B, lane 1). Nonetheless, the reduced levels of c-Myc were
incapable of supporting proliferation, growth, survival, and
tumorigenesis of glioma cancer stem cells. A recent mouse model
of T-cell lymphoma using conditionally expressed c-Myc also
suggest that certain threshold level of c-Myc is required to
maintain the tumor phenotype [42]. Collectively, our results
highlight a necessary requirement of high c-Myc expression in
glioma cancer stem cells.
Cancer stem cells have been proposed as slowly cycling cells, like
their somatic stem cell counterparts [43]. Rapid expansion of tumors
is then dependent on the fast dividing progenitor cells. The slow cell
cycle may provide cancer stem cells a protective mechanism against
certain therapeutic approaches that target rapid proliferating cells.
For example, in human acute myelogenous leukemia, the quiescent
leukemia stem cells are resistant to chemo-drugs that dependent on
cell cycle [44]. Nevertheless, characteristics of cancer stem cells may
not be necessarily uniform across different cancer types, and the
biology of cancer stem cells may change throughout different stages of
tumor development. In brain tumors, Singh and co-workers first
demonstrated that only the CD133+ cancer stem cell population
proliferate in vitro when acutely isolated from human surgical biopsy
specimens [28,29]. These results were similar to the highly
proliferative cancer stem cells that were characterized in a RAS-
induced zebrafish embryonal rhabdomyosarcoma [45]. In the
presentstudy, wedeterminedthattheCD133+gliomacellscontained
a higher percentage of S phase cells and grew faster in vitro than
matched CD1332 cells (Figures 3 and 4). We also found that
proliferation and growth of glioma cancer stem cells were severely
impaired upon knockdown of c-Myc, but importantly, the cell cycle
progression of CD1332 glioma cells were relatively insensitive to loss
of c-Myc. The transcriptional programs regulated by c-Myc remain
poorly defined and dependent on cell state [26,46], but include
inductionofcyclinD1[47]andrepressionofthep21
WAF1/CIP1cyclin-
dependent kinase inhibitor [48,49]. Consistently, expression of cell
cycle regulators downstream of c-Myc, including p21
WAF1/CIP1 and
cyclin D1, was altered in glioma cancer stem cells following c-Myc
knockdown, but not in the CD1332 cells. These data uncover a
Figure 4. Depletion of c-Myc inhibits growth of glioma cancer stem cells. (A) T3359, (B) T3832, and (C) T4597 CD1332 and CD133+ cells
were isolated and infected as described. Cells were then plated in 96-well plates in triplicate at 5000 cells per well for CD1332 cells or 1000 cells per
well for CD133+ cells. Total viable cell numbers were then determined by the CellTiter-Glo Luminescent Cell Viability Assay (Promega) daily. *, p,0.05;
#,p ,0.001 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups on the same day.
doi:10.1371/journal.pone.0003769.g004
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proliferation and growth of the CD133+ glioma cancer stem cells.
Apoptosis can be induced by aberrant expression of certain
oncogenes, such as c-Myc and E2F1, which may act as a ‘‘fail-safe’’
mechanism to eradicate potential cellular transformation [33,50].
Apoptosis induced by c-Myc can be mediated through activation of
theARF-MDM2-p53pathway, or by activatingdeathreceptors, such
as CD95/Fas [33]. However, deregulation of c-Myc is common in
human tumors and is an indicator of poor prognosis because tumors
are well equipped with various anti-apoptosis mechanisms which can
neutralize the apoptotic pressure introduced by c-Myc. Tumorigen-
esis in c-Myc transgenic mouse models is accelerated if combined
with other anti-apoptosis genetic alterations, such as overexpression
of Bcl-2 [51] or Bmi1 [52], or disrupting the ARF-MDM2-p53
pathway [53]. Further, it has been directly demonstrated that
sustained c-Myc activity is required for tumor maintenance in a
variety of conditional transgenic mouse models. These models show
that inactivation of c-Myc almost inevitably results in tumor
regression regardless of tumor type with concomitant growth
inhibition, differentiation, and apoptosis (reviewed in [54]). In some
cases, such as osteosarcoma [55] and skin tumors [56], brief
inactivation of c-Myc is sufficient to induce sustained tumor
regression. However, the dependence on c-Myc can be tumor-type
specific. In certain conditional transgenic models, reactivation of c-
Mycaftertransientdisruptionrestorestumorgrowth[57],whichmay
involve activation of dormant cancer stem cells. Alternatively, tumors
may relapse in a portion of animals even in the absence of c-Myc
activity, suggesting that cancer stem cells may have accumulated
additional mutations to compensate loss of c-Myc [58,59,60]. The
sustained tumor regression may be associated with complete
eradication of cancer stem cells following inactivation of c-Myc,
whereas cancer stem cells may survive and/or escape c-Myc
dependence in recurrent tumors. Our study demonstrated a marked
inductionofapoptosisfollowing c-Mycknockdowninthe cancer stem
cell population (Figure 4), and the cancer stem cells depleted of c-Myc
expression failed to develop orthotopic xenograft tumors in nude
mice(Figure6).Ofparticularinterest,survivalofthenon-stemglioma
cells was not dependent on sustained expression of c-Myc. In a
number of recent studies in other cancer models, targeting c-Myc
expression impaired cellular proliferation and induced senescence
[61,62,63]. These models may represent outcome of loss of c-Myc in
more homogeneous cancer cell populations, particularly genetically
engineered models driven by overexpression of c-Myc. Our study has
important implications as targeting c-Myc has unique benefits specific
to cellular compartments in models representing cellular heteroge-
neity. Although targeting c-Myc was sufficient to prevent tumor
growth in our studies, the dichotomous effects of c-Myc inhibition
that we have detected may support the need to simultaneously target
the non-stem cell tumor populations to achieve clinical efficacy. Thus,
c-Myc as a molecular target must be approached with sophistication
as the majority of tumor cells may demonstrate limited therapeutic
responses but a critical tumor population – the cancer stem cells –
may be inhibited or killed to improve overall tumor control and
decrease resistance to other therapies. Taken together, our study
suggests that the proliferation, growth, and survival of glioma cancer
stem cells are critically dependent on c-Myc expression and that
targeting c-Myc pathways may significantly improve brain tumor
therapy.
Figure 5. Depletion of c-Myc induces apoptosis in glioma cancer stem cells. (A, B) T3359 and (C, D) T4597 CD1332 and CD133+ cells were
isolated and infected as described. (A, C) Six days after infection, cells were trypsinized and quantified for apoptosis using the Annexin V-FITC
Apoptosis Detection kit (Calbiochem). The percentage of FITC positive cells was determined by FACS analysis, and dead cells were excluded by
propidium iodide staining. (B, D) These cells were also plated in 96-well plates at 5000 cells per well for CD1332 cells and 1000 cells per well for
CD133+ cells after infection and selection. Six days after infection, combined activities of caspase 3 and caspase 7 were determined by the Caspase 3/
7 Luminescence Assay kit (Promega), and were normalized by the viable cell numbers determined by the CellTiter-Glo assays as described in Figure 4.
*, p,0.05 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups.
doi:10.1371/journal.pone.0003769.g005
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Cell isolation and culture
Primary glioma surgical biopsy specimens were obtained from
patients undergoing resection for newly diagnosed or recurrent
glioma in accordance with protocols approved by the Duke
University Medical Center Institutional Review Board. Written
consent to utilize excess tissue for research was obtained from each
patient, and de-identified tissues were used for all studies. Cells
were isolated from human glioma surgical specimens and cultured
as previously described [3,9]. Briefly, tumors were dissected,
washed in Earle’s balanced salt solution, digested with papain,
titurated, and filtered. Red blood cells were lysed in diluted
phosphate buffered saline solution (0.256). Glioma cells were then
cultured overnight in stem cell media (neurobasal media
supplemented with B27 and epidermal growth factor and basic
fibroblast growth factor (Invitrogen, Carlsbad, CA) at 20 ng/ml)
prior to cell sorting for recovery of cellular surface antigens. The
CD1332 and CD133+ fractions were separated by magnetic
sorting using the CD133 Microbead kit (Miltenyi Biotec, Auburn,
CA). CD1332 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum (Invitro-
gen), but were cultured in stem cell media at least 24 hours prior
to experiments to control differences in cell media. T3359, T3832,
T4302 and T4597 were originally derived from human glioma
surgical biopsy specimens and were maintained as subcutaneous
xenografts in athymic BALB/c nude mice.
Antibodies
The antibodies used were as follows: Mouse anti-c-Myc
antibody (9E10), FITC-conjugated rabbit anti-c-Myc antibody
(A14), mouse anti-cyclin D1 antibody (DCS-6), rabbit anti-cyclin
D2 antibody (H-289), mouse anti-cyclin E antibody (13A3), mouse
anti-p53 antibody (DO-1) were from Santa Cruz Biotechnology
(Santa Cruz, CA); APC-conjugated mouse anti-CD133 antibody
(AC133-1) was from Miltenyi; goat anti-Olig2 antibody was from
R&D Systems (Minneapolis, MN); mouse anti-p21
WAF1/CIP1
antibody was from Cell signaling Technology (Danvers, MA);
mouse anti-actin antibody was from Millipore (Billerica, MA).
Immunofluorescent staining
Freshly frozen human glioma surgical biopsy samples were
processed and 10 micron sections were mounted on glass slides in
accordance with the Duke University Medical Center Institutional
Figure 6. Depletion of c-Myc attenuates neurosphere formation by glioma cancer stem cells. (A) T3359 CD133+ cells were infected with
lentivirus and selected as described. Cells were then plated at 100 or 10 cells per well in 24-well plates in the presence of 1 mg/ml puromycin. Eight
wells were plated for each group. The numbers of neurospheres in each well were determined in seven days. Spheres that contained more than 20
cells were scored. (B) Percentage of wells without neurospheres formed was quantified. #,p ,0.001 with one-way ANOVA comparison of the control
groups to the corresponding c-Myc knockdown groups. (C) Representative photographs of neurospheres formed by cells expressing non-targeting
shRNA or c-Myc specific shRNA (bars=50 mm). (D, E) Similar results were demonstrated in T4302 CD133+ cells.
doi:10.1371/journal.pone.0003769.g006
Myc Regulates Cancer Stem Cell
PLoS ONE | www.plosone.org 8 November 2008 | Volume 3 | Issue 11 | e3769Review Board. Prior to staining, the sections were fixed in 4%
paraformaldehyde at room temperature for 10 minutes, boiled in
10 mM sodium citrate solution (pH=6.0) for 10 minute, and were
blocked in 10% normal goat serum (Sigma-Aldrich, St. Louis,
MO) and 0.1% Triton X-100 for 30 minutes at room tempera-
ture. Sections were incubated with primary antibodies at 4uC
overnight and secondary antibodies at room temperature for
45 minutes, and then were counterstained with Hoechst 33342
(Invitrogen). For fluorescence imaging, confocal z-stacks were
taken by a 636 water immersion objective lens on a Leica SP-5
microscope using sequential scans (blue-red, green). The following
antibodies were used: mouse anti-c-Myc (Santa Cruz, 1:50), rabbit
anti-Nestin (Abcam, Cambridge, MA, 1:100); goat anti-mouse
IgG1 Alexa 488 (Invitrogen, 1:200), goat anti-rabbit IgG Alexa
568 (Invitrogen, 1:200).
Lentivirus production
The lentiviral vectors directing expression of shRNA specific to
c-Myc (TRCN0000039640 and TRCN0000039641) or a non-
targeting shRNA (SHC002) (Sigma-Aldrich) were co-transfected
with the packaging vectors psPAX2 and pCI-VSVG (Addgene,
Cambridge, MA) into 293FT cells by lipofectamine 2000
(Invitrogen) to produce virus. Two days following transfection,
viral supernatants were collected, filtered, and concentrated by
ultracentrifugation at 100,000 g for 3 hours.
FACS analysis
Glioma cells isolated from surgical biopsy specimens were fixed
in 4% paraformaldehyde, and permeablized in 0.1% Triton X-
100 for 10 minutes. Cells were then washed twice in PBS and
labeled with APC-conjugated CD133 antibody (AC133, 1:11) and
FITC-conjugated c-Myc antibody (A14, 1:50) for 1 hour at room
temperate. Cells were then washed once in PBS and sorted.
Real-time PCR
Total RNA was prepared using the RNeasy kit (Qiagen,
Valencia, CA), and reverse transcribed into cDNA by iScript
cDNA synthesis kit (BioRad, Hercules, CA). Real-time PCR was
performed on an ABI 7900HT system using SYBR-Green
Mastermix (SuperArray, Frederick, MD). PCR products were
verified by melting curves and were also run on a 2% agarose gel to
confirm the appropriate size. The threshold cycle (CT) values for
Figure 7. c-Myc knockdown abolishes xenograft tumor formation by glioma cancer stem cells. (A) T3359 CD133+ cells were infected and
selected as described. After selection, cells were injected into brains of athymic BALB/c nu/nu mice (5000 cells per mouse). Four mice were injected
for each group. Mice in the control group were sacrificed upon the development of neurologic signs. All the mice bearing c-Myc knockdown glioma
cells did not develop neurologic signs and were sacrificed after 100 days without evidence of tumor. Kaplan-Meier survival curves are displayed. (B)
Representative photographs of hematoxylin and eosin staining of intracranial xenograft tumors (106). (C) Xenograft tissue of the control group
composed of pleomorphic cells featuring high nuclear to cytoplasmic ratios, prominent nucleoli with minimal cytoplasm, brisk mitotic activity and
central geographic necrosis (asterisk, 6006). (D) The control glioma xenograft exhibited focal areas of better differentiated tumor cells with relatively
more eosinophilic cytoplasm and cells with eccentric cytoplasmic profiles suggestive of a gemistocytic appearance (arrows, 4006). (E) Xenograft
tumor of the control group exhibits infiltration of tumor cells into the surrounding brain tissue along the margin. The mitotically active (arrowhead)
infiltrating tumor cells exhibit high nuclear to cytoplasmic ratios and elongated fibrillar cytoplasm (arrow) (6006). (F) Mouse brain injected with T3359
cells expressing c-Myc shRNA showed no evidence of tumor at the needle injection site (arrows, 2006).
doi:10.1371/journal.pone.0003769.g007
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HPRT1 (hypoxanthine phosphoribosyltransferase 1). The primers
used were as follows: b-Actin, forward 59-AGAAAATCTGGCAC-
CACACC-39; reverse 59-AGAGGCGTACAGGGATAGCA-39;
HPRT1, forward 59-TGACCTTGATTTATTTTGCATACC-39;
reverse 59-CGAGCAAGACGTTCAGTCCT-39; c-Myc, forward
59-TCAAGAGGCGAACACACAAC-39; reverse 59-GGCCTT-
TTCATTGTTTTCCA-39; cyclin D1, forward 59-CCGCTGG-
CCATGAACTACCT-39; reverse 59-ACGAAGGTCTGCGC-
GTGTT-39; cyclin D2, forward 59-TGGAGCTGCTGTGC-
CACG-39; reverse 59-GTGGCCACCATTCTGCGC-39;
p21
WAF1/CIP1, forward 59-TCACTGTCTTGTACCCTTGTGC-
39; reverse 59-GGCGTTTGGAGTGGTAGAAA-39.
Growth Curve and Neurosphere formation assay
Both CD1332 and CD133+ glioma fractions of glioma cells
were infected by the control lentivirus or lentivirus directing
expression of c-Myc shRNA and were selected with 1 mg/ml
puromycin for 2 days. 5000 CD1332 cells or 1000 CD133+ cells
were plated in 96-well plate in triplicate. Cell number was
measured for 5 consecutive days using the CellTiter-Glo assay kit
(Promega, Madison, MI). Additionally, 100 or 10 CD133+ cells
were seeded per well in 24-well tissue culture plates. Eight wells
were plated for each group. Seven days after plating, neurospheres
containing more than 20 cells were scored.
Intracranial xenograft formation assay
5000 T3359 CD133+ cells lentivirally infected and selected for
expression of the puromycin marker were implanted into brains of
athymic BALB/c nude mice under a Duke University Institutional
Animal Care and Use Committee–approved protocol. Mice were
maintained for 100 days or until development of neurologic signs.
Brains of euthanized mice were collected, fixed in 4% parafor-
maldehyde, paraffin embedded, sectioned, and subjected to
hematoxylin and eosin staining.
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